Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With 131I-Refractory Metastatic Or Unresectable Locally-Advanced Thyroid Cancer

NCT00389441 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00389441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00389441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With 131I-Refractory Metastatic Or Unresectable Locally-Advanced Thyroid Cancer
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2006
Completion date
September 30, 2012
Enrollment
52 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid neoplasms